kynurenine has been researched along with Amyotrophic Lateral Sclerosis in 8 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the kynurenine pathway (KP) and amino acids profile, using mass spectrometry, in the cerebrospinal fluid (CSF) of 42 amyotrophic lateral sclerosis (ALS) patients at the diagnosis and 40 controls to detect early disorders of these pathways." | 8.02 | Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis. ( Alarcan, H; Andres, C; Bakkouche, SE; Benz-De Bretagne, I; Blasco, H; Chaumond, R; Corcia, P; Emond, P; Lefèvre, A; Veyrat-Durebex, C; Vourc'h, P, 2021) |
| " The kynurenine pathway (KP), activated during neuroinflammation, is emerging as a possible contributory factor in ALS." | 7.76 | The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. ( Brew, BJ; Chen, Y; Coggan, S; Cullen, KM; Garner, B; Grant, R; Guillemin, GJ; Meininger, V; Stankovic, R, 2010) |
| " Three potential therapeutic strategies could be feasible to develop drugs to live up to expectations: (1) chemically related drugs with better bioavailability and higher affinity to the binding sites of excitatory receptors; (2) prodrugs of KYNA, which easily cross the blood-brain barrier combined with an inhibitor of organic acid transport for enhancement of the brain KYNA concentration; (3) inhibitors of enzymes of the kynurenine pathway." | 6.48 | The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. ( Bencsik, K; Füvesi, J; Rajda, C; Toldi, J; Vécsei, L, 2012) |
| "The kynurenine pathway (KP) is a major route of L-tryptophan catabolism leading to production of several neurobiologically active molecules." | 6.43 | Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. ( Brew, BJ; Guillemin, GJ; Meininger, V, 2005) |
| "The aim of this study was to evaluate the kynurenine pathway (KP) and amino acids profile, using mass spectrometry, in the cerebrospinal fluid (CSF) of 42 amyotrophic lateral sclerosis (ALS) patients at the diagnosis and 40 controls to detect early disorders of these pathways." | 4.02 | Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis. ( Alarcan, H; Andres, C; Bakkouche, SE; Benz-De Bretagne, I; Blasco, H; Chaumond, R; Corcia, P; Emond, P; Lefèvre, A; Veyrat-Durebex, C; Vourc'h, P, 2021) |
| "Exploring the neurochemical continuum between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) with respect to monoamines and kynurenines in cerebrospinal fluid (CSF) and serum, may be useful to identify possible new research/therapeutic targets." | 3.96 | Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum. ( De Deyn, PP; Janssens, J; Kema, IP; van der Ley, C; van Faassen, M; Vermeiren, Y, 2020) |
| " The kynurenine pathway (KP), activated during neuroinflammation, is emerging as a possible contributory factor in ALS." | 3.76 | The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. ( Brew, BJ; Chen, Y; Coggan, S; Cullen, KM; Garner, B; Grant, R; Guillemin, GJ; Meininger, V; Stankovic, R, 2010) |
| " Three potential therapeutic strategies could be feasible to develop drugs to live up to expectations: (1) chemically related drugs with better bioavailability and higher affinity to the binding sites of excitatory receptors; (2) prodrugs of KYNA, which easily cross the blood-brain barrier combined with an inhibitor of organic acid transport for enhancement of the brain KYNA concentration; (3) inhibitors of enzymes of the kynurenine pathway." | 2.48 | The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. ( Bencsik, K; Füvesi, J; Rajda, C; Toldi, J; Vécsei, L, 2012) |
| "The kynurenine pathway (KP) is a major route of L-tryptophan catabolism leading to production of several neurobiologically active molecules." | 2.43 | Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. ( Brew, BJ; Guillemin, GJ; Meininger, V, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janssens, J | 1 |
| Vermeiren, Y | 1 |
| van Faassen, M | 1 |
| van der Ley, C | 1 |
| Kema, IP | 1 |
| De Deyn, PP | 1 |
| Alarcan, H | 1 |
| Chaumond, R | 1 |
| Emond, P | 1 |
| Benz-De Bretagne, I | 1 |
| Lefèvre, A | 1 |
| Bakkouche, SE | 1 |
| Veyrat-Durebex, C | 1 |
| Vourc'h, P | 1 |
| Andres, C | 1 |
| Corcia, P | 1 |
| Blasco, H | 1 |
| Lee, JM | 1 |
| Tan, V | 1 |
| Lovejoy, D | 1 |
| Braidy, N | 1 |
| Rowe, DB | 1 |
| Brew, BJ | 3 |
| Guillemin, GJ | 4 |
| Chen, Y | 2 |
| Stankovic, R | 1 |
| Cullen, KM | 1 |
| Meininger, V | 3 |
| Garner, B | 1 |
| Coggan, S | 1 |
| Grant, R | 1 |
| Füvesi, J | 1 |
| Rajda, C | 1 |
| Bencsik, K | 1 |
| Toldi, J | 1 |
| Vécsei, L | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
4 reviews available for kynurenine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Humans; Kynurenine; Metabolic Networks and Pathways; Quinoli | 2017 |
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.
Topics: Amyotrophic Lateral Sclerosis; Animals; Humans; Kynurenine; Multiple Sclerosis; Neural Pathways; Pro | 2012 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Humans; Inflammation; Kynurenine; Models, Neurological; Moto | 2005 |
4 other studies available for kynurenine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum.
Topics: Aged; Amyotrophic Lateral Sclerosis; Biogenic Monoamines; Biomarkers; Female; Frontotemporal Dementi | 2020 |
Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis.
Topics: Age of Onset; Aged; Aged, 80 and over; Amino Acids; Amyotrophic Lateral Sclerosis; Biomarkers; Case- | 2021 |
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.
Topics: Adult; Amyotrophic Lateral Sclerosis; Brain; Female; HLA-DR Antigens; Humans; Indoleamine-Pyrrole 2, | 2010 |
Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors.
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Brain; D-Aspartic Acid; Functional Laterality; Humans | 2009 |